Vemurafenib

Zelboraf®

Inhibition of the V600-mutated BRAF kinase.

04/2012

In combination with cobimetinib in non-resectable or metastatic melanoma with a BRAF V600 mutation.

Differential blood count, biochemical panel, glucose, high-sensitivity troponin T, troponin I, NT-proBNP, S-100, blood pressure, ECG (QT time < 500 ms), echocardiography (LVEF > 50%).

Dermatological assessment, ophthalmological examination (in case of ophthalmological symptoms).

Monthly: differential blood count, biochemical panel, glucose, S-100, blood pressure
Monthly (until month 3), then quarterly: ECG (QT interval)
Quarterly: Dermatological examination
After 4 weeks, then quarterly: echocardiography, high-sensitivity troponin T, troponin I, NT-proBNP

Ophthalmological examination for changes in visual acuity

It is recommended to continue treatment until disease progression or unacceptable toxicity occurs.

960 mg orally, twice daily, taken on an empty stomach.

Caution when taking strong CYP2C8 and CYP3A4 inhibitors (e.g. grapefruit, itraconazole) or inducers (e.g. St John's wort, rifampicin, phenytoin, carbamazepine) at the same time.

Refer to the relevant medical literature, guidelines, and study results.